Raltegravir (Isentress®) 25 mg and 100 mg chewable tablets, in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in children are recommended as an option for restricted use within NHS Wales. Raltegravir (Isentress®) 400 mg film-coated tablets, in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infection in adolescents and children from the age of 6 years and weighing ≥ 25 kg, are recommended as an option for restricted use within NHS Wales. Raltegravir (Isentress®) 25 mg and 100 mg chewable tablets and 400 mg film-coated tablets should be restricted for use in patients who are resistant or intolerant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (Pis), or for whom these options are compromised due to drug–drug interactions.